A research study looking at how the compound NNC0194-0499 works with birth control pills in women not able to bear children.

2023-503595-24-00 Protocol NN9500-4619 Human pharmacology (Phase I) - First administration to humans Ended

Start 14 Dec 2023 · End 30 Dec 2024 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol NN9500-4619

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ended
Participants planned 30
Countries 1
Sites 1

Healthy volunteers (Non-alcoholic steatohepatitis (NASH))

Key facts

Sponsor
Novo Nordisk A/S
Participant type
Healthy volunteers
Age range
18-64 years, 65+ years
Gender
Female
Therapeutic area
Diseases [C] - Digestive System Diseases [C06]
Trial duration
14 Dec 2023 → 30 Dec 2024
Decision date (initial)
2023-07-17
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2023-503595-24-00
WHO UTN
U1111-1279-3843

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Healthy volunteers (Non-alcoholic steatohepatitis (NASH))

VersionLevelCodeTermSystem organ class
22.0 PT 10053219 Non-alcoholic steatohepatitis 100000004871

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Novo Nordisk A/S

Sponsor organisation
Novo Nordisk A/S
Address
Novo Alle 1
City
Bagsvaerd
Postcode
2880
Country
Denmark

Scientific contact point

Organisation
Novo Nordisk A/S
Contact name
EU Submission HUB

Public contact point

Organisation
Novo Nordisk A/S
Contact name
EU Submission HUB

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Austria Ended 30 1
Rest of world 0

Investigational sites

Austria

1 site · Ended
Medical University Of Graz
NA, Neue Stiftingtalstrasse 6, 8010, Graz

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Austria 2023-12-14 2024-12-30 2023-12-18 2024-10-14

Application history

4 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2023-04-12 Austria Acceptable
2023-07-10
2023-07-17
2 SUBSTANTIAL MODIFICATION SM-1 2023-07-28 Austria Acceptable
2023-09-11
2023-09-18
3 SUBSTANTIAL MODIFICATION SM-2 2023-10-19 Austria Acceptable
2023-11-24
2023-12-11
4 NON SUBSTANTIAL MODIFICATION NSM-2 2024-03-01 Austria Acceptable
2023-11-24
2024-03-01